-
-
-
-
-
-
-
iTeos Therapeutics (ITOS) GALAXIES Lung-201 of Belrestotug + Dostarlimab did not meet established criteria for clinically meaningful improvements in progression free survival
-
-
-
-
-
-
-
iTeos Therapeutics, Inc. (ITOS) Tops Q3 EPS by 12c
-
-
-
-
-
-
-
iTeos Therapeutics (ITOS) Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at ESMO
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

